Literature DB >> 8957114

IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team.

B Wüthrich1, C Schindler, T C Medici, J P Zellweger, P Leuenberger.   

Abstract

Within the framework of the SAPALDIA survey (Swiss study on Air Pollution and Lung Diseases in Adults), we studied the influence of sex, age and smoking habits on total serum IgE and allergen-specific IgE antibody concentrations (assessed by means of the Phadiatop test) and on the prevalence of hay fever. A total of 8,344 subjects aged 18-60 years, comprising 2,776 current smokers, 1,888 former smokers and 3,680 nonsmokers, were included in the study. Smokers had both a statistically significant (p<0.001) higher mean serum IgE concentration (geometric mean 39.7 kU/l), and a higher percentage (27.5%) of persons with elevated serum IgE (> 100 kU/l) than nonsmokers (27.2 kU/l; respectively 20.5%). The IgE level was significantly lower in women than men (p<0.001) in all smoking categories. The percentage of persons with positive atopic markers (positive Phadiatop test, positive skin prick tests to common inhalant allergens) and self-reported hay fever was significantly higher in nonsmokers than in smokers or former smokers. In Phadiatop positive (atopic) subjects, the IgE levels were highest, with a mean of 104.3 kU/l (99.0-109.8), and lowest in Phadiatop-negative nonsmokers at 27.2 kU/L (25.9-28.6). These findings correlate well with the current interpretation of total serum IgE values in screening for atopic diseases in adults (IgE < 20 kU/l: atopy improbable; IgE > 100 kU/l: atopy probable). In multivariate logistic regression models, the prevalence of positive Phadiatop tests, positive skin tests, and atopy decreased significantly with age. The odds of having a positive Phadiatop and skin test, or being atopic were found to decrease on average by 23.0, 21.1 and 21.0%, respectively, with every 10-year increase in age. With respect to smoking status, the odds ratios for the three atopic markers were significantly lower in current and former smokers than in nonsmokers. The prevalence of (self-reported) hay fever was highest in nonsmokers, intermediate in former smokers (odds ratio = 0.81, p<0.05) and lowest in current smokers (odds ratio = 0.76 in comparison to former smokers, p<0.01). The odds ratio of self-reported current hay fever decreased with age at an estimated average of 23% every 10 years. The decrease in former smokers might be slightly faster than in the other two categories. In conclusion, the present results demonstrated that tobacco smoking is associated with increased IgE levels and negatively related to atopy and hay fever. In addition, it is shown that atopy prevalence decreases with age.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957114     DOI: 10.1159/000237398

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  32 in total

1.  Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors.

Authors:  Neerad C Mishra; Jules Rir-sima-ah; R Thomas Boyd; Shashi P Singh; Sravanthi Gundavarapu; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

2.  Polymorphism in Osteopontin Gene (SPP1) Is Associated with Asthma and Related Phenotypes in a Puerto Rican Population.

Authors:  Mehrdad Arjomandi; Josh M Galanter; Shweta Choudhry; Celeste Eng; Donglei Hu; Kenneth Beckman; Rocío Chapela; José R Rodríguez-Santana; William Rodríguez-Cintrón; Jean Ford; Pedro C Avila; Esteban G Burchard
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-12       Impact factor: 1.349

3.  Increase in exhaled nitric oxide (eNO) after work-related isocyanate exposure.

Authors:  L Barbinova; X Baur
Journal:  Int Arch Occup Environ Health       Date:  2006-01-19       Impact factor: 3.015

4.  Comparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adults.

Authors:  C S Court; D G Cook; D P Strachan
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

5.  Excess risk of temporomandibular disorder associated with cigarette smoking in young adults.

Authors:  Anne E Sanders; William Maixner; Andrea G Nackley; Luda Diatchenko; Kunthel By; Vanessa E Miller; Gary D Slade
Journal:  J Pain       Date:  2011-10-26       Impact factor: 5.820

Review 6.  Role of allergen sensitization in older adults.

Authors:  Ravi K Viswanathan; Sameer K Mathur
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 7.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

8.  Characteristics of allergic sensitization among asthmatic adults older than 55 years: results from the National Health and Nutrition Examination Survey, 2005-2006.

Authors:  Paula J Busse; Richard D Cohn; Paivi M Salo; Darryl C Zeldin
Journal:  Ann Allergy Asthma Immunol       Date:  2013-02-13       Impact factor: 6.347

9.  Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults.

Authors:  S Weidinger; N Klopp; S Wagenpfeil; L Rümmler; M Schedel; M Kabesch; T Schäfer; U Darsow; T Jakob; H Behrendt; H E Wichmann; J Ring; T Illig
Journal:  J Med Genet       Date:  2004-09       Impact factor: 6.318

10.  Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect.

Authors:  Medea Imboden; Joel Schwartz; Christian Schindler; Ivan Curjuric; Wolfgang Berger; Sally L J Liu; Erich W Russi; Ursula Ackermann-Liebrich; Thierry Rochat; Nicole M Probst-Hensch
Journal:  Environ Health Perspect       Date:  2009-05-26       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.